Personalizing the Path in mCRPC: Optimizing Chemotherapy and Aggressive Variant Prostate Cancer (AVPC) - Episode 6

Balancing Intensity, Duration, and Maintenance in Treatment

,

A panel of experts discuss first-line treatment selection for AVPC/NEPC comparing platinum-etoposide regimens versus carboplatin with cabazitaxel or docetaxel, including considerations of dose reductions, cycle length, and doublet intensity.

EP. 1: The Role of Chemotherapy in Today’s mCRPC Landscape
EP. 2: Overcoming Barriers to Cabazitaxel and Optimizing Sequencing
EP. 3: Individualizing Chemotherapy: Dosing, Tolerability, and Treatment Duration
EP. 4: Recognizing and Treating AVPC
EP. 5: Integrating Immunotherapy – Lessons from Small Cell Lung Cancer
Now Viewing
EP. 6: Balancing Intensity, Duration, and Maintenance in Treatment
EP. 7: Biomarkers, Disease Tracking, and Tumor Evolution

This discussion compares platinum–etoposide regimens with combinations such as carboplatin plus cabazitaxel or docetaxel in the first-line setting. Experts review practical considerations including dosing intensity, planned dose reductions, cycle length, and cumulative toxicity. The panel stresses balancing efficacy with tolerability, particularly in older or frail patients, and adapting treatment intensity based on early response and adverse events rather than rigid adherence to predefined regimens.